Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | POLB | P06746 | 3/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | P2RY11 | Q96G91 | 1/20 | 0.33 |
| ▸ | HRAS | P01112 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | GAPDH | P04406 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL881368 | 0.82 | MAPT (0.35) | ALDH1A1POLBMEN1USP2KMT2A | |
| SCHEMBL10186058 | 0.82 | MAPT (0.35) | ALDH1A1POLBMEN1USP2KMT2A | |
| SCHEMBL12398065 | 0.82 | MAPT (0.35) | ALDH1A1POLBMEN1USP2KMT2A | |
| SCHEMBL10149693 | 0.80 | MEN1 (0.38) | ALDH1A1POLBMEN1USP2KMT2A | |
| SCHEMBL882554 | 0.80 | MEN1 (0.38) | ALDH1A1POLBMEN1USP2KMT2A | |
| SCHEMBL12243221 | 0.80 | MAPT (0.33) | ALDH1A1POLBMEN1USP2KMT2A | |
| SCHEMBL12243138 | 0.80 | ALDH1A1 (0.33) | ALDH1A1POLBMEN1USP2KMT2A | |
| SCHEMBL881794 | 0.78 | ALDH1A1 (0.35) | ALDH1A1POLBHTTTDP1LMNA | |
| SCHEMBL882455 | 0.75 | MAPT (0.39) | ALDH1A1POLBMEN1USP2KMT2A | |
| SCHEMBL15084427 | 0.75 | ALDH1A1 (0.34) | ALDH1A1POLBHTTTDP1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3150608-A1 | 2' -FLUORO SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | Gilead Sciences, Inc. (US) | 2017-04-05 | — | — | EP | disclosed |
| EP-2480552-B1 | 2' -FLUORO SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES INC (US) | 2016-11-09 | — | — | EP | disclosed |
| US-8455451-B2 | 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2013-06-04 | — | — | US | disclosed |
| US-8455451-B2 | 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2013-06-04 | — | — | US | disclosed |
| WO-2012039787-A1 | 2' -FLUORO SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2012-03-29 | — | — | WO | disclosed |
| WO-2012039791-A1 | 2' -FLUORO SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2012-03-29 | — | — | WO | disclosed |
| US-20120009147-A1 | 2'-FLUORO SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2012-01-12 | — | — | US | disclosed |
| US-20120009147-A1 | 2'-FLUORO SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2012-01-12 | — | — | US | disclosed |
| US-7973013-B2 | 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2011-07-05 | — | — | US | disclosed |
| US-7973013-B2 | 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2011-07-05 | — | — | US | disclosed |
| US-20110070194-A1 | 2'-FLUORO SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2011-03-24 | — | — | US | disclosed |
| US-20110070194-A1 | 2'-FLUORO SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2011-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120009147-A1 | 2'-FLUORO SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | PNP, NSUN2, CDA | ALDH1A1 1783/4885POLB 794/4885MEN1 4845/4885 |
| US-20110070194-A1 | 2'-FLUORO SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | PNP, RNGTT, SLC29A1 | ALDH1A1 1619/4885POLB 648/4885MEN1 4874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.